3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Partial nephrectomy or ablation; active surveillance for small tumours; no adjuvant therapy.
Thermal ablation uses an applicator to heat or freeze selected tissue. Safe coverage and later local control need assessment beyond placing the device.
For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Sunitinib, cabozantinib, everolimus or lenvatinib plus everolimus; immunotherapy has low response rates outside sarcomatoid disease; trials preferred.
Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.
A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.
An mTOR-blocking pill that doubled progression-free time with exemestane in 2012 and is now paired with the oral SERD giredestrant.
An oral anti-angiogenic pill that matched sorafenib in liver cancer with higher response rates, and partners with pembrolizumab in kidney and endometrial cancer.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · Pancreatic NET phase 3 (n=83), US label | 27% | 10% |
| Hand-foot syndrome · Pancreatic NET phase 3 (n=83), US label | 23% | 6% |
| Diarrhoea · Pancreatic NET phase 3 (Study 6, n=83), US label | 59% | 5% |
| Nausea · Pancreatic NET phase 3 (n=83), US label | 45% | 1% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hand-foot skin reaction · CELESTIAL, cabozantinib after sorafenib in HCC (n=467), US label: palmar-plantar erythrodysesthesia | 46% | 17% |
| Hypertension · CELESTIAL (n=467), US label | 30% | 16% |
| Diarrhoea · CELESTIAL (n=467), US label | 54% | 10% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Stomatitis · BOLERO-2, everolimus plus exemestane (n=482), US label | 67% | 8% |
| Hyperglycaemia · BOLERO-2 adverse reaction (n=482), US label; laboratory hyperglycaemia 69% | 14% | 5% |
| Pneumonitis · BOLERO-2 (n=482), US label | 19% | 4% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · REFLECT, lenvatinib in first-line HCC (n=476), US label; no grade 4 | 45% | 24% |
| Proteinuria · REFLECT (n=476), US label | 26% | 6% |
| Decreased appetite · REFLECT (n=476), US label; decreased weight 31% (8% grade 3-4) | 34% | 5% |
| Diarrhoea · REFLECT (n=476), US label | 39% | 4% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Kidney surveillance with MRI, nephron-sparing surgery at 3 cm, and genetic counselling.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.